| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| John Lauriello, Peter J Weiden, Carole D Gleeson, Ankit Shah, Luke Boulanger, Krutika Jariwala-Parikh, Elizabeth Hedgeman, Amy K O'Sulliva. Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia. CNS drugs. vol 35. issue 10. 2021-11-09. PMID:34546558. |
real-world outcomes and costs following 6 months of treatment with the long-acting injectable (lai) aripiprazole lauroxil for the treatment of schizophrenia. |
2021-11-09 |
2023-08-13 |
Not clear |
| John Lauriello, Peter J Weiden, Carole D Gleeson, Ankit Shah, Luke Boulanger, Krutika Jariwala-Parikh, Elizabeth Hedgeman, Amy K O'Sulliva. Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia. CNS drugs. vol 35. issue 10. 2021-11-09. PMID:34546558. |
the lai aripiprazole lauroxil (al) was approved in the united states (us) in 2015 for the treatment of schizophrenia in adults. |
2021-11-09 |
2023-08-13 |
Not clear |
| b' Vjekoslav Peitl, Vivian A Bad\\xc5\\xbeim, Ines \\xc5\\xa0i\\xc5\\xa1ko Marko\\xc5\\xa1, Ana Renduli\\xc4\\x87, Krunoslav Mate\\xc5\\xa1i\\xc4\\x87, Dalibor Karlovi\\xc4\\x8. Improvements of Frontotemporal Cerebral Blood Flow and Cognitive Functioning in Patients With First Episode of Schizophrenia Treated With Long-Acting Aripiprazole. Journal of clinical psychopharmacology. vol 41. issue 6. 2021-11-05. PMID:34459433.' |
improvements of frontotemporal cerebral blood flow and cognitive functioning in patients with first episode of schizophrenia treated with long-acting aripiprazole. |
2021-11-05 |
2023-08-13 |
Not clear |
| b' Vjekoslav Peitl, Vivian A Bad\\xc5\\xbeim, Ines \\xc5\\xa0i\\xc5\\xa1ko Marko\\xc5\\xa1, Ana Renduli\\xc4\\x87, Krunoslav Mate\\xc5\\xa1i\\xc4\\x87, Dalibor Karlovi\\xc4\\x8. Improvements of Frontotemporal Cerebral Blood Flow and Cognitive Functioning in Patients With First Episode of Schizophrenia Treated With Long-Acting Aripiprazole. Journal of clinical psychopharmacology. vol 41. issue 6. 2021-11-05. PMID:34459433.' |
the objective of this study was to investigate whether use of aripiprazole in its long-acting injectable formulation (alai), during a 3-month treatment, has beneficial effects on cbf and cognitive functioning in patients with first episode of schizophrenia. |
2021-11-05 |
2023-08-13 |
Not clear |
| Hidenobu Suzuki, Hiroyuki Hibin. Comparison of treatment retention between risperidone long-acting injection, paliperidone palmitate, and aripiprazole once-monthly in elderly patients with schizophrenia. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society. 2021-11-03. PMID:34729877. |
comparison of treatment retention between risperidone long-acting injection, paliperidone palmitate, and aripiprazole once-monthly in elderly patients with schizophrenia. |
2021-11-03 |
2023-08-13 |
Not clear |
| Henry A Nasrallah, Peter J Weiden, David P Walling, Yangchun Du, Baiyun Yao, Sergey Yagoda, Amy Claxto. Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study. BMC psychiatry. vol 21. issue 1. 2021-10-25. PMID:34625041. |
aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled alpine study. |
2021-10-25 |
2023-08-13 |
Not clear |
| Henry A Nasrallah, Peter J Weiden, David P Walling, Yangchun Du, Baiyun Yao, Sergey Yagoda, Amy Claxto. Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study. BMC psychiatry. vol 21. issue 1. 2021-10-25. PMID:34625041. |
a randomized, controlled, phase 3b study (alpine) evaluated efficacy and safety of a 2-month formulation of aripiprazole lauroxil (al) using a 1-day initiation regimen in patients hospitalized for an acute exacerbation of schizophrenia. |
2021-10-25 |
2023-08-13 |
Not clear |
| Deanna L Kelly, Amy Claxton, Ilda Bidollari, Yangchun D. Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil. Psychiatry research. vol 302. 2021-10-22. PMID:34118485. |
analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil. |
2021-10-22 |
2023-08-13 |
Not clear |
| Ling Zhang, Han Qi, Yun-Yi Xie, Wei Zheng, Xiao-Hui Liu, Dong-Bin Cai, Chee H Ng, Gabor S Ungvari, Yu-Tao Xian. Efficacy and Safety of Adjunctive Aripiprazole, Metformin, and Paeoniae-Glycyrrhiza Decoction for Antipsychotic-Induced Hyperprolactinemia: A Network Meta-Analysis of Randomized Controlled Trials. Frontiers in psychiatry. vol 12. 2021-10-22. PMID:34658963. |
aripiprazole, metformin, and paeoniae-glycyrrhiza decoction (pgd) have been widely used as adjunctive treatments to reduce antipsychotic (ap)-induced hyperprolactinemia in patients with schizophrenia. |
2021-10-22 |
2023-08-13 |
human |
| Ling Zhang, Han Qi, Yun-Yi Xie, Wei Zheng, Xiao-Hui Liu, Dong-Bin Cai, Chee H Ng, Gabor S Ungvari, Yu-Tao Xian. Efficacy and Safety of Adjunctive Aripiprazole, Metformin, and Paeoniae-Glycyrrhiza Decoction for Antipsychotic-Induced Hyperprolactinemia: A Network Meta-Analysis of Randomized Controlled Trials. Frontiers in psychiatry. vol 12. 2021-10-22. PMID:34658963. |
a network meta-analysis of randomized controlled trials (rcts) was conducted to compare the efficacy and safety between aripiprazole, metformin, and pgd as adjunctive medications in reducing ap-induced hyperprolactinemia in schizophrenia. |
2021-10-22 |
2023-08-13 |
human |
| Peter J Weiden, Yangchun Du, Lisa von Moltke, Angela Wehr, Marjie Hard, Morteza Marandi, David P Wallin. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. CNS drugs. vol 34. issue 9. 2021-10-20. PMID:32621071. |
aripiprazole lauroxil (al) is a long-acting injectable antipsychotic approved for treatment of schizophrenia in adults. |
2021-10-20 |
2023-08-13 |
Not clear |
| Liang Zheng, Shiwei Tang, Rui Tang, Miao Xu, Xuehua Jiang, Ling Wan. Dose Adjustment of Quetiapine and Aripiprazole for Pregnant Women Using Physiologically Based Pharmacokinetic Modeling and Simulation. Clinical pharmacokinetics. vol 60. issue 5. 2021-10-15. PMID:33251573. |
quetiapine and aripiprazole are currently prescribed for pregnant women to treat schizophrenia and bipolar disorder. |
2021-10-15 |
2023-08-13 |
Not clear |
| Tommaso Toffanin, Alessandro Miola, Benedetta Salvati, Francesco Folena Comini, Chiara Pavan, Giorgio Pigato, Fabio Sambatar. Long-Acting Aripiprazole in the Management of Violence in Treatment Nonadherent Schizophrenia. The primary care companion for CNS disorders. vol 23. issue 1. 2021-10-15. PMID:33445228. |
long-acting aripiprazole in the management of violence in treatment nonadherent schizophrenia. |
2021-10-15 |
2023-08-13 |
Not clear |
| Pedro Such, Martin Bøg, Madhu S Kabra, Kristian T Jørgensen, Anne C de Jong-Lair. A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-Onset Schizophrenia. The primary care companion for CNS disorders. vol 23. issue 5. 2021-10-15. PMID:34592798. |
a noninterventional cohort study assessing time to all-cause treatment discontinuation after initiation of aripiprazole once monthly or daily oral atypical antipsychotic treatment in patients with recent-onset schizophrenia. |
2021-10-15 |
2023-08-13 |
Not clear |
| Christopher Evernden, Irene Giang, Mariah Anderso. The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia. The mental health clinician. vol 11. issue 5. 2021-10-09. PMID:34621608. |
the use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia. |
2021-10-09 |
2023-08-13 |
Not clear |
| Nora Palomar-Ciria, Marta Migoya-Borja, Fanny Cegla-Schvartzman, Santiago Ovejero, Raquel Alvarez-Garcia, Hugo J Bello, Enrique Baca-Garcí. Early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical report. International clinical psychopharmacology. vol 36. issue 2. 2021-10-04. PMID:33492014. |
early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical report. |
2021-10-04 |
2023-08-13 |
Not clear |
| Nora Palomar-Ciria, Marta Migoya-Borja, Fanny Cegla-Schvartzman, Santiago Ovejero, Raquel Alvarez-Garcia, Hugo J Bello, Enrique Baca-Garcí. Early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical report. International clinical psychopharmacology. vol 36. issue 2. 2021-10-04. PMID:33492014. |
fifty-one patients suffering an acute episode of schizophrenia and treated with aripiprazole long-acting injectable (alai) were chosen to elaborate an observational study in two in-patient units in spain, in order to examine the effects of early administration during a hospital admission. |
2021-10-04 |
2023-08-13 |
Not clear |
| Nobuhisa Kanahara, Masayuki Takase, Tsuyoshi Sasaki, Masanori Honma, Yasutaka Fujita, Shigenori Tadokoro, Hitoshi Suzuki, Hiroshi Yamanaka, Shingo Noda, Satoshi Yanahashi, Takahisa Saiga, Naoya Komatsu, Takeshi Simoyama, Masaomi Iy. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. International clinical psychopharmacology. vol 35. issue 6. 2021-09-28. PMID:32868522. |
the effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. |
2021-09-28 |
2023-08-13 |
Not clear |
| Nobuhisa Kanahara, Masayuki Takase, Tsuyoshi Sasaki, Masanori Honma, Yasutaka Fujita, Shigenori Tadokoro, Hitoshi Suzuki, Hiroshi Yamanaka, Shingo Noda, Satoshi Yanahashi, Takahisa Saiga, Naoya Komatsu, Takeshi Simoyama, Masaomi Iy. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. International clinical psychopharmacology. vol 35. issue 6. 2021-09-28. PMID:32868522. |
the present study was conducted to examine whether very slowly switching to aripiprazole could help patients with schizophrenia with dopamine supersensitivity while avoiding rebound psychosis. |
2021-09-28 |
2023-08-13 |
Not clear |
| Minami Tasaki, Norio Yasui-Furukori, Saaya Yokoyama, Masataka Shinozaki, Norio Sugawara, Kazutaka Shimod. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. Neuropsychopharmacology reports. vol 41. issue 3. 2021-09-21. PMID:34189861. |
hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. |
2021-09-21 |
2023-08-13 |
Not clear |